[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100349611":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":11,"centralContacts":15,"locations":25,"responsibleParty":44,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",null,[9],{"type":6,"name":10,"description":10,"armGroupLabels":7,"otherNames":7},"Leftover surgical tissue homogenization",[12],{"name":13,"affiliation":5,"role":14},"Samra Turajlic","STUDY_CHAIR",[16,22],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Serena Vanzan","CONTACT","020 3186 5161","5161","vault@rmh.nhs.uk",{"name":23,"role":18,"phone":7,"phoneExt":7,"email":24},"Eleanor Carlyle","Renal&Melanoma.researchteam@rmh.nhs.uk",[26],{"facility":27,"status":28,"city":29,"state":7,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Royal Marsden Hospital NHS Foundation Trust","RECRUITING","London","SW3 6JJ","United Kingdom","UK",{"type":34,"coordinates":35},"Point",[36,37],-0.12574,51.50853,{"lat":37,"lon":36},[40],{"name":41,"role":18,"phone":42,"phoneExt":7,"email":43},"Ann Gandolfi","02086613903","ann.gandolfi@rmh.nhs.uk",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[47],{"name":48,"class":49},"Ventana Medical Systems","UNKNOWN","100349611","value-of-analysing-under-utilised-leftover-tissue-vault-100349611",false,"NCT03832062","Value of Analysing Under-utilised Leftover Tissue (VauLT)","VauLT","Inclusion Criteria:\n\n1. Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery.\n2. Tissues for Research consent has been provided.\n3. Patient age \\>18yo.\n4. Minimum of 1 gram of residual tumour remaining in leftover surgical tissue\n5. Minimum of 1 gram of normal tissue present.\n\nExclusion Criteria:\n\n1. Advanced Practitioner in histological dissection deems tumour sample to be inadequate.\n2. Leftover surgical tumour tissue greater than 20kg.","ALL","18 Years",{"count":60,"type":61},800,"ESTIMATED","OBSERVATIONAL","Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.",[65],"Oncology","2025-05-14",{"date":68,"type":69},"2025-05-18","ACTUAL",{"date":71,"type":69},"2018-09-10",{"date":73,"type":61},"2028-12-31",{"name":5,"class":6},1]